


Siren Biotechnology is the world's first #AAV #GeneTherapy company targeting #cancer.


🔥 @SirenBio has been named Biotechnology Innovator of the Year in the 2026 @BioTech_Awards! We’re honored to be recognized as SRN-101 enters the clinic for high-grade glioma. Thank you to our team, collaborators, and the patients and families who drive this work every day. Read more: biotechbreakthroughawards.co…

Headed to @ASGCTherapy Breakthroughs in Cell and Gene Therapy in Nashville next week? Don’t miss @SirenBio's CEO and Founder @Nicole_Paulk speaking about our Universal AAV Immuno-Gene Therapy Platform. See you there! 👋 Thursday, November 12, 2026 1:30 PM – 3:00 PM CT Room: Tennessee C

Congratulations @SirenBio's SAB member Susan Kaech @Tcellogic on her election to @theNAMedicine for her outstanding scientific and technical achievements in the field of immunology!!!
I’m honored to be welcomed into @theNAMedicine. I share this recognition with all the students, postdocs, and colleagues in my lab. Your curiosity, hard work, and fearlessness in tackling big questions have driven everything we have achieved. Thank you. #NAMmtg

We gave Léa Bouhelier-Gautreau from @kingscrowdinc a peak into our lab. 🎥 Léa spent a day with our team in San Francisco, watched how our science is done, and spoke with @Nicole_Paulk about where we’re headed. Her verdict on the people doing the work? “Very approachable, very fun, and at the same time extremely professional.” - We’ll take it! 😉 Two FDA-cleared INDs later, that same team is now bringing SRN-101 to the clinic. Watch the visit below. Let’s change the future of cancer care, together. youtube.com/watch?v=wmfmKDmC…

📣 @SirenBio is pleased to announce the appointment of Dr. Peter Bross, MD, former Chief of the Oncology Branch at the FDA’s Center for Biologics Evaluation and Research (CBER), to our Clinical and Scientific Advisory Board! Dr. Bross brings more than 25 years of FDA experience reviewing novel oncology therapies, including gene and cell therapies, immunotherapies, and oncolytic viruses. His expertise comes at an important time as we advance SRN-101, our lead Universal #AAV Immuno #GeneTherapy candidate, into the clinic for recurrent high-grade glioma. Welcome, Dr. Bross! Read more at globenewswire.com/news-relea…

@SirenBio is thrilled to welcome Ford H-Kirschenbaum to our Translational team! Ford brings 30 years of biotech experience building cell-based, biomarker, and bioanalytical assays for preclinical and clinical programs. At Siren, he is the driver of our translational assay development, in our own lab and with our external partners, as SRN-101 moves through the clinic. Welcome to the team, Ford!

🔥 @SirenBio's CEO and Founder @Nicole_Paulk has been named as one of the 2026 @endpts Women in Biopharma! We're so proud to celebrate Nicole's leadership in bringing Universal #AAV Immuno #GeneTherapy to patients with #cancer. Read more: endpoints.news/special-repor… #WomenInBiopharma #Leadership #GeneTherapy #oncology

The @SirenBio team is headed to #Boston this week for Cell & Gene Therapy International @CellTherapyIC! Catch Nathalie Clement and Lauren Kelly on Friday, when they’ll be sharing a behind-the-scenes glimpse of the CMC and nonclinical strategy that led to Siren’s first IND. Don’t miss it!

We’re excited to attend the Cell and Gene Therapy Symposium co-hosted by @UCSD, @CALifeSciences, and @CIRMnews! Our CEO, @Nicole, will be sharing the latest developments at @SirenBio and how we’re advancing #AAV Immuno #GeneTherapy to the clinic. Register & learn more below!👇 genetherapy.ucsd.edu/symposi…

We are thrilled to welcome Mary Bearkland, Senior Director of Clinical Operations, to the @SirenBio team! Mary brings more than 25 years of clinical operations leadership, having directed Phase I–III trials from first-in-human studies to regulatory submission and contributed to two FDA-approved therapies. She will lead our clinical operations as we advance SRN-101, our Universal #AAV Immuno #GeneTherapy, through the clinic. Welcome to the team, Mary!

🎉 Congratulations to Christine Xie on wrapping up a successful summer internship at @SirenBio! Christine, a student at @Stanford, spent the summer generating business development materials that guide Siren's strategic positioning as we advance our Universal #AAV Immuno #GeneTherapy for #Cancer. Her work will continue to serve the team long after her last day. Please join us in congratulating Christine and wishing her all the best as she heads back to Stanford this fall!

September is #ChildhoodCancerAwarenessMonth, and @SirenBio is thinking of every child and family facing a cancer diagnosis. Every step we take to advance Universal #AAV #GeneTherapy for #Cancer is for the patients and families who need better options. Let's sound the alarm against #cancer! #GoldSeptember #GoGold


📣 BIG news to close out the week! @SirenBio has been awarded an $8M non-dilutive CLIN2 grant from @CIRMnews to support our Phase 1/2 clinical trial of SRN-101 in adult recurrent high-grade glioma! We're incredibly grateful to CIRM and the vision and support of all Californians. Let's sound the alarm against #cancer! Read the press release: globenewswire.com/news-relea…

On #WorldBrainTumorDay, @SirenBio stands with every patient and family living with a brain tumor. Brain tumors like high-grade glioma are among the hardest cancers to treat, and that urgency drives everything we do. We're advancing SRN-101, our #AAV Immuno #GeneTherapy for high-grade glioma, to the clinic for patients who need it most. Let's sound the alarm against #cancer!